Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 5377 with Last Name = 'hawkins' and Initial = 'j'
TargetChymase(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50208224(2-(3-((1-(2-naphthoyl)piperidin-4-yl)(methyl)carba...)
Affinity DataKi:  2.30nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
TargetChymase(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50208222((E)-2-(3-chloro-5-fluorostyrylamino)-1-(5-chlorobe...)
Affinity DataKi:  11nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  17.5nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  20nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  21nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetChymase(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50208228(1-(5-chlorobenzo[b]thiophen-3-yl)-2-(naphthalen-2-...)
Affinity DataKi:  36nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
TargetCathepsin G(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50208224(2-(3-((1-(2-naphthoyl)piperidin-4-yl)(methyl)carba...)
Affinity DataKi:  38nMAssay Description:Inhibition of human neutrophil Cat GMore data for this Ligand-Target Pair
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  41nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  51nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetB1 bradykinin receptor(Human)
Elan Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50222653((S)-alpha-[[[4-bromo-5-[(2-chlorobenzoyl)amino]-1H...)
Affinity DataKi:  73nMAssay Description:Displacement of [3H]DAKA from human bradykinin B1 receptor in IL1beta stimulated IMR90 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  96nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetB1 bradykinin receptor(Human)
Elan Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50222669(4-bromo-5-[(2-chlorobenzoyl)amino]-N-[2-(4-pyridin...)
Affinity DataKi:  120nMAssay Description:Displacement of [3H]DAKA from human bradykinin B1 receptor in IL1beta stimulated IMR90 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetB1 bradykinin receptor(Human)
Elan Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50222657(4-bromo-5-[(2-chlorobenzoyl)amino]-N-phenyl-1H-pyr...)
Affinity DataKi:  200nMAssay Description:Displacement of [3H]DAKA from human bradykinin B1 receptor in IL1beta stimulated IMR90 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  200nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  200nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  210nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  1.10E+3nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM50045050(1-(3-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopen...)
Affinity DataKi:  1.90E+3nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  2.00E+3nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
LigandPNGBDBM85683(Co 2-6749 | Co-2-6749 | GMA-839 | WAY-141839)
Affinity DataKi:  2.30E+3nMMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCathepsin G(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50208228(1-(5-chlorobenzo[b]thiophen-3-yl)-2-(naphthalen-2-...)
Affinity DataKi:  9.50E+3nMAssay Description:Inhibition of human neutrophil Cat GMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium/potassium-transporting ATPase subunit alpha-4/beta-1(Rat)
University of Minnesota

Curated by ChEMBL
LigandPNGBDBM50255109(CHEMBL4081196)
Affinity DataIC50:  0.00200nMAssay Description:Inhibition of recombinant rat Na+/K+-ATPase alpha4/beta1 expressed in baculovirus infected insect Sf9 cell membranes using [gamma-32P]ATP as substrat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium/potassium-transporting ATPase subunit alpha-4/beta-1(Rat)
University of Minnesota

Curated by ChEMBL
LigandPNGBDBM50255111(CHEMBL4092961)
Affinity DataIC50:  0.0110nMAssay Description:Inhibition of recombinant rat Na+/K+-ATPase alpha4/beta1 expressed in baculovirus infected insect Sf9 cell membranes using [gamma-32P]ATP as substrat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetB1 bradykinin receptor(Human)
Elan Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50222656(4-bromo-5-[(2-chlorobenzoyl)amino]-N-[4-[2-(4,5-di...)
Affinity DataIC50:  0.0750nMAssay Description:Antagonist activity at human bradykinin B1 receptor in IL1beta stimulated IMR90 cells by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664353(N-(5-(2-(3,3-Dimethylazetidin- 1-yl)acetamido)-2- ...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664241(N-(5-(2-(5-azaspiro[2.4]heptan- 5-yl)acetamido)-2-...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664388(N-(5-(2- (cyclobutylamino)acetamido)- 2-methylpyri...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664033(N-(5-((2-(6-azaspiro[3.4]octan- 6-yl)ethyl)carbamo...)
Affinity DataIC50: <0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664204(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664205(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664200(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664201(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664203(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664160(N-(5-(3-(2,2-dimethylpyrrolidin- 1-yl)propanamido)...)
Affinity DataIC50:  0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664226((R)-N-(5-(2-(1- isopropylpyrrolidin-2- yl)acetamid...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664326(2-(5,6-dihydro-4H-pyrrolo[1,2- b]pyrazol-3-yl)-N-(...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664230(2-(2-methoxypyridin-3-yl)-N-(2- methyl-5-(2-(pyrro...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664218((S)-2-(2-methoxypyridin-3-yl)- N-(2-methyl-5-((2-(...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664351(2-(1,5-Dimethyl-1H-pyrazol-4- yl)-N-(5-(2-(3,3- di...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664361(2-(1,3-Dimethyl-1H-pyrazol-4- yl)-N-(5-(2-(2,2- di...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664365(N-(5-(2-(2,2-dimethylpyrrolidin- 1-yl)acetamido)-2...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664237(N-(5-(2-(2-oxa-7- azaspiro[4.4]nonan-7- yl)acetami...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664238(N-(5-(2-(5-azaspiro[2.5]octan-5- yl)acetamido)-2-m...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664240((S)-N-(5-(2-(1- isopropylpyrrolidin-2- yl)acetamid...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664391(N-(5-(2-(5- azaspiro[2.4]heptan-5- yl)acetamido)-2...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664392(N-(5-(2-(1- azaspiro[3.3]heptan-1- yl)acetamido)-2...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664393(2-(6,7-dihydro-4H- pyrazolo[5,1-c][1,4]oxazin-3- y...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664378(N-(5-((2-(5-azaspiro[3.4]octan- 5-yl)ethyl)carbamo...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM663993((S)-N-(5-(2-(3- ethylmorpholino)acetamido)-2- meth...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664270(N-(5-(2-(1-azaspiro[3.3]heptan- 1-yl)acetamido)-2-...)
Affinity DataIC50:  0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

Displayed 1 to 50 (of 5377 total ) | Next | Last >>
Jump to: